New Oral Drugs Show Promise in Lowering LDL Cholesterol & Heart Risk

For individuals at high cardiovascular risk, two experimental oral medications – enlicitid and obicetrapib – could significantly change the treatment of high cholesterol. Despite many people failing to reach acceptable LDL levels even with strict medical care, these molecules offer new possibilities.

Promising Results in Clinical Trials

Enlicitid was tested in an international clinical trial involving nearly 3,000 patients with athérosclérose or risk factors. According to a study published in the New England Journal of Medicine, the medication reduced LDL cholesterol by an average of 60% after 24 weeks. “Less than half of patients with proven atherosclerotic cardiovascular disease currently reach the targets set for LDL cholesterol,” notes Ann Marie Navar, a cardiologist and principal investigator at UT Southwestern Medical centre.

Did You Know? The enlicitid trial involved nearly 3,000 patients internationally, highlighting the scale of research into new cholesterol-lowering treatments.

Impact on Lipid Levels

Beyond lowering LDL cholesterol, enlictid also demonstrated effectiveness on other lipid markers like lipoprotéine(a), apolipoprotéine B and lipoprotéines non-HDL. These biomarkers are all involved in the development of serious cardiovascular diseases. Navar specifies that “These reductions in LDL cholesterol are, by far, the largest we have ever obtained with an oral drug since the development of statins.” These results were sustained for a year, bolstering confidence in the treatment.

Obicetrapib: A Second Potential Breakthrough

A separate study of over 2,500 patients showed that obicetrapib reduced LDL by an average of 32.6%. Its effectiveness also extends to lipoprotéine(a), reducing it by 33.5%. This dual action is considered unprecedented. Currently, no approved oral treatment effectively targets this molecule, which is strongly correlated with the risk of heart attack and stroke.

Expert Insight: The ability of obicetrapib to address both LDL cholesterol and lipoprotéine(a) represents a potentially significant advancement, as current treatments often focus solely on LDL.

Synergistic Effects with Combination Therapy

Another trial evaluated the effect of a fixed combination of obicetrapib and ézétimibe, another lipid-lowering medication. Conducted across 48 centers in the United States, the study showed a 48.6% reduction in LDL cholesterol, compared to 31.9% for obicetrapib alone. The combination therapy appears to be well-tolerated, with a comparable rate of side effects to the individual treatments. Researchers suggest this combination could become a new standard therapy for complex cases.

Looking Ahead

While the data is encouraging, researchers remain cautious. Both trials primarily measured the effect on blood levels, not directly on heart attacks or strokes. Further studies will be needed to establish long-term clinical benefits. However, the FDA has granted enlicitid a “National Priority Voucher,” a mechanism to accelerate regulatory evaluation.

Frequently Asked Questions

What did the enlicitid trial demonstrate?

The enlicitid trial, involving nearly 3,000 patients, demonstrated an average 60% reduction in LDL cholesterol after 24 weeks.

What makes obicetrapib unique?

Obicetrapib uniquely reduces both LDL cholesterol and lipoprotéine(a) by 32.6% and 33.5% respectively, a dual action not currently available in approved oral treatments.

What is a National Priority Voucher?

A National Priority Voucher, awarded to enlicitid by the FDA, is a device designed to accelerate the regulatory evaluation process for the medication.

Given these promising developments, how might these new oral medications reshape the future of cardiovascular disease management for high-risk patients?